CRTPF - Cardiol posts topline results from early-stage heart disease study

Cardiol Therapeutics (CRTPF) posts positive topline results from a Phase I single and multiple ascending dose clinical trial of CardiolRx, an oral cannabidiol formulation being developed for the treatment of acute and chronic inflammation associated with heart disease.The Phase I trial was a randomized, placebo-controlled, double-blind study designed to evaluate the safety, tolerability, and pharmacokinetic ((PK)) profile of CardiolRx at various dose levels.Topline results showed that CardiolRx was safe and generally well tolerated at all dose levels, with no serious adverse events reported in the study.Results are expected to support the company's plans to file an IND application with the FDA for a Phase II international trial in acute myocarditis.

For further details see:

Cardiol posts topline results from early-stage heart disease study